Tumor antigen presentation: Changing the rules

Todd D. Armstrong, Beth A. Pulaski, Suzanne Ostrand-Rosenberg

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Cell-based tumor vaccines have been developed on the basis of the hypothesis that tumor cells can be genetically modified to present antigen to T lymphocytes directly. Contrary to expectations, cross-priming is the predominant pathway for activation of tumor-specific CD8+ T cells, while direct presentation of antigen dominates activation of tumor-specific CD4+ T cells. These results pose interesting paradoxes for the generation of immune responses, and have definite implications for the development of anti-cancer vaccines.

Original languageEnglish (US)
Pages (from-to)70-74
Number of pages5
JournalCancer Immunology Immunotherapy
Issue number2
StatePublished - 1998


  • Cell-based cancer vaccines
  • Cross- priming
  • Immuno herapy
  • MHC class II
  • Tumor antigen presentation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Tumor antigen presentation: Changing the rules'. Together they form a unique fingerprint.

Cite this